An Observational Study to Determine the Prevalence of COVID-19 Among Hospitalized Patients With Multidrug-Resistant Enterobacterales Infections and Clinical Outcomes, 10 US Sites, 2020-2022OPEN FORUM INFECTIOUS DISEASESIF3.82024-12-260OA
Carbapenem-resistant Acinetobacter baumannii complex in the United States-An epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019美国耐碳青霉烯类鲍曼不动杆菌复合体-通过新兴感染计划收集的分离株的流行病学和分子描述,2019AMERICAN JOURNAL OF INFECTION CONTROLIF2.42024-09-017OAAI
Carbapenem-Resistant and Extended-Spectrum β-Lactamase- Producing Enterobacterales in Children, United States, 2016-2020EMERGING INFECTIOUS DISEASESIF6.62024-06-010OAAI
Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI RecurrencesOPEN FORUM INFECTIOUS DISEASESIF3.82024-03-062OA
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022OPEN FORUM INFECTIOUS DISEASESIF3.82023-09-086OA
Carbapenem-Resistant enterobacterales in individuals with and without health care risk factors -Emerging infections program, United States, 2012-2015AMERICAN JOURNAL OF INFECTION CONTROLIF2.42023-01-0116OAAI
Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected through CDC's Emerging Infections Program, United States, 2016-2018ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52022-09-2017OA
Low Sensitivity of International Classification of Diseases, Tenth Revision Coding for Culture-Confirmed Candidemia Cases in an Active Surveillance System: United States, 2019-2020OPEN FORUM INFECTIOUS DISEASESIF3.82022-09-072OA
Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013OPEN FORUM INFECTIOUS DISEASESIF3.82022-08-176OA
Epidemiology of extended-spectrum β-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYIF32022-02-1415OA
Risk Factors for SARS-CoV-2 Infection Among US Healthcare Personnel, May-December 2020EMERGING INFECTIOUS DISEASESIF6.62022-01-0113OAAI
The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) PandemicCLINICAL INFECTIOUS DISEASESIF7.32021-06-18101OA
Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018CLINICAL INFECTIOUS DISEASESIF7.32021-06-0314OA
Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United StatesMBIOIF4.72021-02-2343OAAI
Association between Socioeconomic Status and Incidence of Community-Associated Clostridioides difficile Infection - United States, 2014-2015CLINICAL INFECTIOUS DISEASESIF7.32021-01-199OA
Evaluation of Discrepancies in Carbapenem Minimum Inhibitory Concentrations Obtained at Clinical Laboratories Compared to a Public Health LaboratoryINFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYIF32020-11-021OA
Characteristics of Cases With Polymicrobial Bloodstream Infections Involving Candida in Multisite Surveillance, 2017INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYIF32020-11-020OA
Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected Through the Emerging Infections ProgramINFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYIF32020-11-020OAAI
Trends in US Burden of Clostridioides difficile Infection and OutcomesNEW ENGLAND JOURNAL OF MEDICINEIF78.52020-04-02535OAAI